All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone
The study lays the proof-of-concept for virus-free all-in-one GMP-manufacturing of glucocorticoid-resistant CAR T-cell products. Further, the glucocorticoid-resistant gp350-CAR T cells can provide a future therapeutic option for high-risk post-transplant patients with EBV-reactivations or patients with EBV-associated pathologies requiring steroid treatment.
Authors
- Renata Stripecke (ORCID: https://orcid.org/0000-0001-7756-8460)
- Tobias F. Feuchtinger (ORCID: https://orcid.org/0000-0002-8517-9681)
- Paulina Ferrada‐Ernst
- Reinhard Zeidler (ORCID: https://orcid.org/0000-0002-3357-4954)
- Lena Jablonowski
- Semjon Manuel Willier (ORCID: https://orcid.org/0000-0001-9472-2191)
- Theresa Kaeuferle (ORCID: https://orcid.org/0009-0005-2122-7794)
- Dana Stenger
- Nadine Stoll
- Abdallah AHA Yassin
- Maximilian Zwermann
Institutions
- University of Freiburg (DE)
- German Cancer Research Center (DE)
- University of Cologne (DE)
- University of Würzburg (DE)
- University Medical Center Freiburg (DE)
- Helmholtz Zentrum München (DE)
- LMU Klinikum (DE)
- Medizinische Hochschule Hannover (DE)
- Düsseldorf University Hospital (DE)
- German Center for Infection Research (DE)
- University Hospital Cologne (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1186/s40164-025-00631-w
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09